Black Friday Get Elite for just $149.00 Claim Now

CG Oncology Reports 68% Reduction in Bladder Cancer Recurrence Risk in Phase 3 PIVOT-006 Trial

By Fiona Craig | November 16, 2026, 11:02 AM

CG Oncology, Inc. (NASDAQ:CGON) announced that its Phase 3 PIVOT-006 clinical trial met its primary endpoint, demonstrating a 68% reduction in the risk of bladder cancer recurrence among patients receiving its investigational treatment cretostimogene grenadenorepvec compared with the control group.

The registrational study evaluated cretostimogene in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC) following complete tumour resection.

The trial demonstrated a statistically significant improvement in recurrence-free survival, with a hazard ratio of 0.32, a 95% confidence interval of 0.23 to 0.45 and a p-value below 0.0001.

Median follow-up was 17 months as of October 26, 2026.

Phase 3 Trial Meets Primary Endpoint

PIVOT-006 enrolled 367 patients across approximately 90 clinical sites in the United States and Canada.

The randomised study compared intravesical cretostimogene treatment with surveillance following complete tumour removal.

Participants included patients with recurrent low-grade Ta disease, multifocal low-grade tumours, solitary high-grade Ta tumours measuring no more than 3 cm and low-grade T1 disease.

CG Oncology reported improvements in recurrence-free survival across both high-grade and low-grade patient populations.

The company estimates that approximately 50,000 patients in the United States fall within the population targeted by the study, for which there are currently no FDA-approved adjuvant treatment options.

Treatment Shows No Grade 3 or Higher Related Adverse Events

CG Oncology reported that cretostimogene was generally well tolerated, with a safety profile consistent with previous clinical studies.

No Grade 3 or higher treatment-related adverse events were observed, and no patients discontinued treatment because of treatment-related adverse events.

Cretostimogene is an investigational oncolytic immunotherapy administered directly into the bladder.

The treatment has been evaluated in a clinical development programme involving more than 700 patients with non-muscle invasive bladder cancer.

Its safety and efficacy have not yet been established by the US Food and Drug Administration or another regulatory authority.

CG Oncology Targets Second-Quarter 2027 Regulatory Filing

Following the PIVOT-006 results, CG Oncology plans to complete a Biologics License Application (BLA) submission for cretostimogene in intermediate-risk and high-grade Ta NMIBC during the second quarter of 2027.

The company is also expanding the scope of a separate regulatory application covering patients with Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC.

The original application focused on patients with carcinoma in situ (CIS), with or without papillary tumours.

Following feedback from the FDA, CG Oncology intends to include patients with high-grade papillary-only disease in the submission.

To incorporate the additional clinical data, the company now expects to complete the BCG-unresponsive NMIBC application before the end of March 2027.

CG Oncology said all manufacturing activities required to support both planned regulatory submissions have been completed.

Arthur Kuan, Chairman, President and Chief Executive Officer of CG Oncology, commented on the results and regulatory plans.

“We are working expeditiously to complete our BLA filing in intermediate-risk and HG Ta NMIBC in the second quarter of 2027,” Kuan said.

He added that the company is seeking a broader regulatory label covering the full range of BCG-unresponsive patients.

Clinical Development Programme Covers Multiple Bladder Cancer Populations

Cretostimogene is being evaluated across several patient groups through CG Oncology’s clinical development programme.

In addition to PIVOT-006, the company is conducting the Phase 3 BOND-003 trial in patients with BCG-unresponsive NMIBC.

Its CORE-008 study is evaluating cretostimogene in BCG-exposed high-risk, BCG-naïve high-risk and BCG-unresponsive patient populations.

The treatment has received FDA Fast Track and Breakthrough Therapy designations for BCG-unresponsive NMIBC.

CG Oncology has also initiated an Expanded Access Programme in North America for eligible patients whose disease has not responded to BCG treatment.

The company said the PIVOT-006 results could support an expansion of cretostimogene’s potential patient population if regulatory approval is obtained.

Its next regulatory milestones include the planned BLA submissions in March and the second quarter of 2027, with any eventual commercialisation dependent on regulatory review and approval.

CG Oncology stock price

Mentioned In This Article

Latest News

Nov-16
Nov-16
Nov-16
Nov-16
Nov-16
Nov-16
Nov-16
Nov-16
Nov-06
Oct-13
Sep-11
Sep-02
Aug-06
Jul-27
May-28